Go or no go? Roche’s fresh start for a new year

Go or no go? Roche’s fresh start for a new year

Submitted by admin on December 20, 2021 - 10:59am
Source: 
EP Vantage
News Tags: 
FDA
Roche
Novartis
Pfizer
AstraZeneca
Cibinqo
Lynparza
Tezspire
Vyvgart
faricimab
Headline: 
Go or no go? Roche’s fresh start for a new year
snippet: 

2022 will kick off with key FDA decisions for Roche, Novartis and Pfizer, while Astrazeneca will be hoping to extend its Lynparza franchise even further.

Do Not Allow Advertisers to Use My Personal information